Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
<h4>Background</h4>During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of thi...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2012
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|